References
- Shiohara T, Kano Y. Review of drug-induced hypersensitivity: special emphasis on drug-induced hypersensitivity syndrome. Expert Rev Dermatology. 2012;7:539–547.
- Kardaun SH, Sekula P, Veleyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective regiSCAR study. Br J Dermatol. 2013;169:1071–1080.
- Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DiHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006;55:1–8.
- Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol. 2004;140:183–188.
- Kano Y, Hirahara K, Sakuma K, et al. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006;155:301–306.
- Descamps V, Avenel-Audran M, Veleyrie-Allanore L, et al. Saliva polymerase chain reaction assay dor detection and follow-up of bherpes virus reactivation in patients with drug reaction with eosinophilia and systemic symptoms (DRESS). JAMA Dermatol. 2013;149:565–569.
- Picard D, Janela B, Descamps V, et al. Drug rash with eosinophilia and systemic symptoms(DRESS): a multiorgan antiviral T cell responses. Sci Transl Med. 2010;2:46–62.
- Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its finding and the type of drug eruption. Allergy. 2007;62:1439–1444.
- Takahashi R, Kano Y, Yamazaki Y, et al. Defective regulatory T cells in patients with severe drug eruption: timing of the dysfunction is associated with the pathological phenotype and outcome. J. Immunol. 2009;182:8071–8079.
- Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126–1133.
- Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2010;20:1034–1041.
- Asano Y, Kagawa H, Kano Y, et al. Cytomegalovirus disease during severe drug eruption: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol. 2009;145:1030–1036.
- Ushigome Y, Kano Y, Ishida T, et al. Short- and long-term outcome of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2015;68:721–728.
- Shiohara T, Kurata M, Mizukawa Y, et al. Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy. Allergol Int. 2010;59:333–343.
- Takehara A, Aoyama Y, Kurosawa M, et al. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in DiHS/DRESS. Br J Dermatol. 2016;175:944–952.